CASI PHARMACEUTICALS
CASI Pharmaceuticals, Inc. ("CASI", "we" or "us") is a U.S. biopharmaceutical company focused on developing and commercializing innovative therapeutics and pharmaceutical products in China, the United States, and throughout the world. CASI is focused on acquiring, developing and commercializing products that augment its hematology oncology therapeutic focus as well as other areas of unmet medical need. CASI is executing its plan to become a biopharmaceutical leader by launching medicines in the greater China market leveraging CASI's China-based regulatory and commercial competencies and its global drug development expertise.
CASI PHARMACEUTICALS
Industry:
Biotechnology Medical Pharmaceutical
Founded:
1991-01-01
Address:
Rockville, Maryland, United States
Country:
United States
Website Url:
http://www.casipharmaceuticals.com
Total Employee:
101+
Status:
Active
Contact:
(240) 864-2643
Total Funding:
147.38 M USD
Technology used in webpage:
Viewport Meta IPhone / Mobile Compatible SPF SSL By Default Google Font API Google Analytics Apple Mobile Web Clips Icon Google Universal Analytics Nginx Euro
Similar Organizations
Advanced Cell Diagnostics
Advanced Cell Diagnostics is a molecular pathology company developing cell- and tissue-based diagnostic tests for personalized medicine.
Salix Pharmaceuticals
Salix Pharmaceuticals is a specialty pharmaceutical company focused on the prevention and treatment of gastrointestinal disorders.
Current Employees Featured
Ken Keyong Ren CEO @ CASI Pharmaceuticals
CEO
2013-04-04
John W Holaday co-founder @ CASI Pharmaceuticals
co-founder
Alexander A. Zukiwski CMO @ CASI Pharmaceuticals
CMO
2017-04-01
James Goldschmidt Senior Vice President of Business Development @ CASI Pharmaceuticals
Senior Vice President of Business Development
2016-04-01
Elisabeth Uible Corporate Communications @ CASI Pharmaceuticals
Corporate Communications
2019-08-01
Founder
Stock Details
Acquisitions List
| Date | Company | Article | Price |
|---|---|---|---|
| 2006-01-10 | Miikana Therapeutics | Miikana Therapeutics acquired by CASI Pharmaceuticals | 9.96 M USD |
Investors List
Robert W. Duggan
Robert W. Duggan investment in Post-IPO Equity - CASI Pharmaceuticals
ETP Fund
ETP Fund investment in Post-IPO Equity - CASI Pharmaceuticals
IDG Capital
IDG Capital investment in Post-IPO Equity - CASI Pharmaceuticals
IDG Capital
IDG Capital investment in Post-IPO Equity - CASI Pharmaceuticals
Emerging Technology Partners
Emerging Technology Partners investment in Post-IPO Equity - CASI Pharmaceuticals
Accel
Accel investment in Post-IPO Equity - CASI Pharmaceuticals
Oxford Finance LLC
Oxford Finance LLC investment in Post-IPO Debt - CASI Pharmaceuticals
GE Healthcare
GE Healthcare investment in Post-IPO Debt - CASI Pharmaceuticals
Merrill Lynch
Merrill Lynch investment in Post-IPO Debt - CASI Pharmaceuticals
Investments List
| Date | Company | Article | Money raised |
|---|---|---|---|
| 2022-07-08 | Precision Autoimmune Therapeutics | CASI Pharmaceuticals investment in Venture Round - Precision Autoimmune Therapeutics | 140 M CNY |
| 2019-07-09 | Juventas | CASI Pharmaceuticals investment in Series A - Juventas | 100 M CNY |
Official Site Inspections
http://www.casipharmaceuticals.com Semrush global rank: 1.53 M Semrush visits lastest month: 17.33 K
- Host name: staticip2.multiscreensite.com
- IP address: 100.24.208.97
- Location: Ashburn United States
- Latitude: 39.0481
- Longitude: -77.4728
- Metro Code: 511
- Timezone: America/New_York
- Postal: 20149
More informations about "CASI Pharmaceuticals"
CASI Pharmaceuticals
CID-103 is an investigational monoclonal antibody. Its targets include B memory, plasmablasts, and B plasma cells. The anti-CD38 approach aims to address limitations seen with CD19 and …See details»
CASI Pharmaceuticals - Wikipedia
CASI Pharmaceuticals, previously known as EntreMed is a US based pharmaceutical company developing medicinal treatments for cancer. The company is primarily known for its producing the angiogenesis inhibitor Endostatin. In 2014 the company was renamed to CASI Pharmaceuticals to focus on products for the treatments of myeloma, leukemia, lymphoma. Wei-Wu He is the present chairman and CEO of the company. See details»
CASI Pharmaceuticals | Management
Dr. He has served as chairman to the board of directors and CEO of CASI since 2019, as executive chairman from February, 2018, and as chairman from February 2012.See details»
CASI Pharmaceuticals - Crunchbase Company Profile & Funding
Contact Email ir@casipharmaceuticals.com Phone Number (240) 864-2643 CASI Pharmaceuticals, Inc. ("CASI", "we" or "us") is a U.S. biopharmaceutical company focused on …See details»
CASI Pharmaceuticals, Inc. - Company Profile & Staff Directory
CASI is a U.S. NASDAQ-listed biopharmaceutical company focused on developing and accelerating the launch of innovative therapeutics and pharmaceutical products in China, U.S., …See details»
CASI Pharmaceuticals | Investor Overview
CASI Pharmaceuticals, Inc. is followed by the analyst(s) listed below. This list is provided for information purposes only. Please note that any opinions, estimates or forecasts regarding CASI Pharmaceutical' s performance made by these …See details»
CASI Pharmaceuticals Inc
CASI Pharmaceuticals, Inc., a clinical-stage pharmaceutical company, develops therapeutics to treat cancer and other diseases primarily in the United States and China.See details»
CASI Pharmaceuticals, Inc. (CASI) Company Profile & Facts - Yahoo …
See the company profile for CASI Pharmaceuticals, Inc. (CASI) including business summary, industry/sector information, number of employees, business summary, corporate governance, …See details»
CASI Pharmaceuticals, Inc. | LinkedIn
CASI Pharmaceuticals, Inc. | 1,122 followers on LinkedIn. Bringing life-changing therapeutics to China and the world. | CASI is a U.S. NASDAQ-listed biopharmaceutical company focused …See details»
CASI Pharmaceuticals, Inc. (CASI) Company Profile & Overview
Jun 11, 1996 1701-1702, China Central Office Tower 1, No. 81 Jianguo Road Beijing, 100025 ChinaSee details»
CASI Pharmaceuticals Company Profile | Management and
Smith@casipharmaceuticals.com: CASI Pharmaceuticals Top Competitors. Company Employees Revenue Top technologies; Mirati Therapeutics Inc. 587: $38.2 M: Heron Therapeutics Inc. …See details»
CASI Pharmaceuticals Inc. Company Profile & Executives - WSJ
Company profile for CASI Pharmaceuticals Inc. including key executives, insider trading, ownership, revenue and average growth rates. View detailed CASI description & address.See details»
CASI Pharmaceuticals - Overview, News & Similar companies
Mar 28, 2024 View CASI Pharmaceuticals (www.casipharmaceuticals.com) location in China , revenue, industry and description. Find related and similar companies as well as employees …See details»
CASI Pharmaceuticals - Products, Competitors, Financials, …
CASI Pharmaceuticals Announces Third Quarter 2024 Business and Financial Results. Nov 15, 2024. Press Release• updated: Nov 15, 2024 08:00 EST BEIJING, CHINA, November 15, …See details»
CASI Pharmaceuticals, Inc. Overview | SignalHire Company Profile
CASI is a U.S. NASDAQ-listed biopharmaceutical company focused on developing and accelerating the launch of innovative therapeutics and pharmaceutical products in China, U.S., …See details»
CASI Pharmaceuticals - Craft
Aug 15, 2024 CASI Pharmaceuticals has 5 employees across 2 locations and $43.11 m in annual revenue in FY 2022. See insights on CASI Pharmaceuticals including office locations, …See details»
TECHNOLOGY - CASI Pharmaceuticals
CASI is a NASDAQ-listed biopharmaceutical company focused on developing and commercializing innovative therapeutics and pharmaceutical products.See details»
CASI Pharmaceuticals, Inc. (CASI) - Stock Analysis
4 days ago Website https://www.casipharmaceuticals.com. Full Company Profile. Financial Performance. In 2023, CASI Pharmaceuticals's revenue was $33.88 million, a decrease of …See details»
CASI Stock Price Quote | Morningstar
Jan 10, 2025 See the latest CASI Pharmaceuticals Inc stock price (CASI:XNAS), related news, valuation, dividends and more to help you make your investing decisions.See details»
CASI Pharmaceuticals | Press Releases
CASI is a NASDAQ-listed biopharmaceutical company focused on developing and commercializing innovative therapeutics and pharmaceutical products.See details»